Articles by Sarah Houlton - Pharmaceutical Executive

ADVERTISEMENT

Articles by Sarah Houlton

Elan Hits Bottom

Aug 1, 2002

Donal Geaney and Tom Lynch, chairman/CEO and vice-chairman, respectively, of the troubled Irish pharma company Elan, resigned following intense pressure from investors.

Drug Info War Heats Up

Aug 1, 2002

The debate about direct-to-consumer (DTC) advertising of prescription medicines and internet information about therapeutic products is heating up again. Non-product-specific disease awareness campaigns are now allowed. In fact, Europeans were recently treated to retired Brazilian soccer star PelĘsponsored by Pfizer) urging the afflicted to seek help for erectile dysfunction during World Cup commercial breaks .

Internet to the Rescue

Aug 1, 2002

In response to concerns about the low level of patient participation in clinical trials, the British Medical Association has launched an internet resource aimed at encouraging more patients to take part. Aimed at healthcare professionals, the site explains how different types of trials are conducted and spells out their ethical and best practices requirements.

East Meets West

Aug 1, 2002

Croatia's Pliva Pharmaceuticals is the first eastern European pharma company to make a US acquisition. Pliva paid $153 million for New Jersey-based Sobel Holdings,

Not So NICE

Aug 1, 2002

The United Kingdom's much-maligned National Institute for Clinical Excellence (NICE) could be in line for a shake-up if the recommendations of a House of Commons select committee go through.

AIDS Conference Cites Breakthroughs

Aug 1, 2002

Activist protests about access to, and the price of, AIDS medicines marked the International AIDS conference in Barcelona. But they failed to overshadow the promising results of research into new ways of attacking the virus.

Australia Tackles Prescription Costs

Jul 1, 2002

The Australian government has an unusual plan for reducing prescription drug costs: enlist the help of pharma sales reps to explain the country's pharmaceutical benefits scheme (PBS) prescribing requirements to doctors.

Priming the European Pipeline

Jul 1, 2002

With the huge costs of developing a new drug from scratch and the high attrition rates as lead compounds fail during the trials process, in-licensing has become an increasingly popular method for pharma companies to boost their pipelines without all of the outlay involved in de novo research.

Genome Key to World Health

The World Health Organization issues a call to ensure that all countries benefit from future healthcare advances, regardless of their ability to fund research.
Jul 1, 2002

The decoding of the human genome and its potential to open the door to cures for AIDS, cancer, and many other conditions that today are incurable are likely to shapethe healthcare industry for decades to come.

ADVERTISEMENT

Click here